Genetic Polymorphisms in Dopamine- and Serotonin-Related Genes and Treatment Responses to Risperidone and Perospirone
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We investigated the possible association between genetic polymorphisms in the dopamine receptor and serotonin transporter genes and the responses of schizophrenic patients treated with either risperidone or perospirone. The subjects comprised 27 patients with schizophrenia who were clinically evaluated both before and after treatment. The genotyping of the polymorphisms of the dopamine D2 receptor gene (DRD2) (rs1801028 and rs6277), the dopamine D4 receptor gene (DRD4) (120-bp tandem repeats and rs1800955), and serotonin transporter gene (5HTT)(variable number of tandem repeats; VNTR) were performed using the real-time polymerase chain reaction and sequencing. In DRD2 and 5HTT-VNTR, there were no significant correlations between clinical response and polymorphism in the case of risperidone, and for perospirone treatment it was impossible to analyze the clinical evaluation due to the absence of genotype information. On the other hand, in DRD4 there were significant correlations in the two-factor interaction effect on the Positive and Negative Syndrome Scale (PANSS) between the two drugs [120-bp tandem repeat, p=0.003; rs1800955, p=0.043]. Although the small sample represents a serious limitation, these results suggest that variants in DRD4 are a predictor of whether treatment will be more effective with risperidone or with perospirone in individual patients.
Abstract
We investigated the possible association between genetic polymorphisms in the dopamine receptor and serotonin transporter genes and the responses of schizophrenic patients treated with either risperidone or perospirone. The subjects comprised 27 patients with schizophrenia who were clinically evaluated both before and after treatment. The genotyping of the polymorphisms of the dopamine D2 receptor gene (DRD2) (rs1801028 and rs6277), the dopamine D4 receptor gene (DRD4) (120-bp tandem repeats and rs1800955), and serotonin transporter gene (5HTT)(variable number of tandem repeats; VNTR) were performed using the real-time polymerase chain reaction and sequencing. In DRD2 and 5HTT-VNTR, there were no significant correlations between clinical response and polymorphism in the case of risperidone, and for perospirone treatment it was impossible to analyze the clinical evaluation due to the absence of genotype information. On the other hand, in DRD4 there were significant correlations in the two-factor interaction effect on the Positive and Negative Syndrome Scale (PANSS) between the two drugs [120-bp tandem repeat, p=0.003; rs1800955, p=0.043]. Although the small sample represents a serious limitation, these results suggest that variants in DRD4 are a predictor of whether treatment will be more effective with risperidone or with perospirone in individual patients.
참고문헌 (14)
- Xing Q, "The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients", Int J Neuropsychopharmacol, 10, pp.631~637 (2007)
- Wang L, "Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients", Neurosci Lett, 414, pp.1~4 (2007)
- Xuan J, "Tang W, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response:a pharmacogenetic study", Neuropsychopharmacology, 22, pp.305~311 (2008)
- Dolzan V, "Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment", Am J Med Genet B Neuropsychiatr Genet, 144B, pp.809~815 (2007)
- Allen NC, "Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database", Nat Genet, 40, pp.827~834 (2008)
- Hirose A, "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions", Jpn J Pharmacol, 53, pp.321~329 (1990)
- Sakamoto H, "Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent", Pharmacol Biochem Behav, 60, pp.873~878 (1998)
- Shiwa T, "Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor", J Pharmacol Sci, 93, pp.114~117 (2003)
- Togo T, "Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone", J Pharmacol Sci, 91, pp.259~262 (2003)
- Wang E, "The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus", Am J Hum Genet, 74, pp.931~944 (2004)
- D’Souza UM, "Functional effects of a tandem duplication polymorphism in the 5’flanking region of the DRD4 gene", Biol Psychiatry, 56, pp.691~697 (2004)
- Okuyama Y, "A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia", Biochem Biophys Res Commun, 258, pp.292~295 (1999)
- Stefanis NC, "Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain", Brain Res Mol Brain Res, 53, pp.112~119 (1998)
- Lidow MS, "Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum:effects of chronic treatment with typical and atypical antipsychotic drugs", J Pharmacol Exp Ther, 283, pp.939~946 (1997)